J P Mohr1, Michael K Parides2, Christian Stapf3, Ellen Moquete2, Claudia S Moy4, Jessica R Overbey2, Rustam Al-Shahi Salman5, Eric Vicaut6, William L Young7, Emmanuel Houdart8, Charlotte Cordonnier9, Marco A Stefani10, Andreas Hartmann11, Rüdiger von Kummer12, Alessandra Biondi13, Joachim Berkefeld14, Catharina J M Klijn15, Kirsty Harkness16, Richard Libman17, Xavier Barreau18, Alan J Moskowitz2. 1. The Neurological Institute, Columbia University Medical Center, New York, NY, USA. 2. International Center for Health Outcomes and Innovation Research, Department of Health Evidence and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 3. The Neurological Institute, Columbia University Medical Center, New York, NY, USA; Department of Neurology, APHP-Hôpital Lariboisière, Univ Paris Diderot-Sorbonne Paris Cité, Paris, France; DHU NeuroVasc, APHP-Hôpital Lariboisière, Univ Paris Diderot-Sorbonne Paris Cité, Paris, France. Electronic address: christian.stapf@lrb.aphp.fr. 4. National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA. 5. Division of Clinical Neurosciences, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK. 6. Unité de Recherche Clinique, APHP-Hôpital Lariboisière, Univ Paris Diderot-Sorbonne Paris Cité, Paris, France. 7. Department of Anesthesia and Perioperative Care, University of California, San Francisco, CA, USA. 8. Department of Neuroradiology, APHP-Hôpital Lariboisière, Univ Paris Diderot-Sorbonne Paris Cité, Paris, France. 9. Department of Neurology, CHRU Lille, Université Lille Nord de France, Lille, France. 10. Department of Neurology and Neurosurgery, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil. 11. Charité-Universitätsmedizin Berlin Berlin, Germany; Department of Neurology, Klinikum Frankfurt/Oder, Frankfurt/Oder Oder, Germany. 12. Department of Neuroradiology, University Hospital Dresden, Dresden, Germany. 13. Department of Neuroradiology and Endovascular Therapy, Jean Minjoz Hospital, University of Franche Comté, Besançon, France. 14. Department of Neuroradiology, Universitätsklinikum Frankfurt, Frankfurt am Main, Germany. 15. Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus, University Medical Center, Utrecht, Netherlands. 16. Department of Neurology, Royal Hallamshire Hospital, Sheffield, UK. 17. Department of Neurology, North Shore Long Island Jewish Medical Center, New Hyde Park, NY, USA. 18. Department of Diagnostic and Interventional Neuroimaging, CHU Pellegrin, Bordeaux, France.
Abstract
BACKGROUND: The clinical benefit of preventive eradication of unruptured brain arteriovenous malformations remains uncertain. A Randomised trial of Unruptured Brain Arteriovenous malformations (ARUBA) aims to compare the risk of death and symptomatic stroke in patients with an unruptured brain arteriovenous malformation who are allocated to either medical management alone or medical management with interventional therapy. METHODS: Adult patients (≥18 years) with an unruptured brain arteriovenous malformation were enrolled into this trial at 39 clinical sites in nine countries. Patients were randomised (by web-based system, in a 1:1 ratio, with random permuted block design [block size 2, 4, or 6], stratified by clinical site) to medical management with interventional therapy (ie, neurosurgery, embolisation, or stereotactic radiotherapy, alone or in combination) or medical management alone (ie, pharmacological therapy for neurological symptoms as needed). Patients, clinicians, and investigators are aware of treatment assignment. The primary outcome is time to the composite endpoint of death or symptomatic stroke; the primary analysis is by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00389181. FINDINGS: Randomisation was started on April 4, 2007, and was stopped on April 15, 2013, when a data and safety monitoring board appointed by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health recommended halting randomisation because of superiority of the medical management group (log-rank Z statistic of 4·10, exceeding the prespecified stopping boundary value of 2·87). At this point, outcome data were available for 223 patients (mean follow-up 33·3 months [SD 19·7]), 114 assigned to interventional therapy and 109 to medical management. The primary endpoint had been reached by 11 (10·1%) patients in the medical management group compared with 35 (30·7%) in the interventional therapy group. The risk of death or stroke was significantly lower in the medical management group than in the interventional therapy group (hazard ratio 0·27, 95% CI 0·14-0·54). No harms were identified, other than a higher number of strokes (45 vs 12, p<0·0001) and neurological deficits unrelated to stroke (14 vs 1, p=0·0008) in patients allocated to interventional therapy compared with medical management. INTERPRETATION: The ARUBA trial showed that medical management alone is superior to medical management with interventional therapy for the prevention of death or stroke in patients with unruptured brain arteriovenous malformations followed up for 33 months. The trial is continuing its observational phase to establish whether the disparities will persist over an additional 5 years of follow-up. FUNDING: National Institutes of Health, National Institute of Neurological Disorders and Stroke.
BACKGROUND: The clinical benefit of preventive eradication of unruptured brain arteriovenous malformations remains uncertain. A Randomised trial of Unruptured Brain Arteriovenous malformations (ARUBA) aims to compare the risk of death and symptomatic stroke in patients with an unruptured brain arteriovenous malformation who are allocated to either medical management alone or medical management with interventional therapy. METHODS: Adult patients (≥18 years) with an unruptured brain arteriovenous malformation were enrolled into this trial at 39 clinical sites in nine countries. Patients were randomised (by web-based system, in a 1:1 ratio, with random permuted block design [block size 2, 4, or 6], stratified by clinical site) to medical management with interventional therapy (ie, neurosurgery, embolisation, or stereotactic radiotherapy, alone or in combination) or medical management alone (ie, pharmacological therapy for neurological symptoms as needed). Patients, clinicians, and investigators are aware of treatment assignment. The primary outcome is time to the composite endpoint of death or symptomatic stroke; the primary analysis is by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00389181. FINDINGS: Randomisation was started on April 4, 2007, and was stopped on April 15, 2013, when a data and safety monitoring board appointed by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health recommended halting randomisation because of superiority of the medical management group (log-rank Z statistic of 4·10, exceeding the prespecified stopping boundary value of 2·87). At this point, outcome data were available for 223 patients (mean follow-up 33·3 months [SD 19·7]), 114 assigned to interventional therapy and 109 to medical management. The primary endpoint had been reached by 11 (10·1%) patients in the medical management group compared with 35 (30·7%) in the interventional therapy group. The risk of death or stroke was significantly lower in the medical management group than in the interventional therapy group (hazard ratio 0·27, 95% CI 0·14-0·54). No harms were identified, other than a higher number of strokes (45 vs 12, p<0·0001) and neurological deficits unrelated to stroke (14 vs 1, p=0·0008) in patients allocated to interventional therapy compared with medical management. INTERPRETATION: The ARUBA trial showed that medical management alone is superior to medical management with interventional therapy for the prevention of death or stroke in patients with unruptured brain arteriovenous malformations followed up for 33 months. The trial is continuing its observational phase to establish whether the disparities will persist over an additional 5 years of follow-up. FUNDING: National Institutes of Health, National Institute of Neurological Disorders and Stroke.
Authors: R P Atkinson; I A Awad; H H Batjer; C F Dowd; A Furlan; S L Giannotta; C R Gomez; D Gress; G Hademenos; V Halbach; J C Hemphill; R T Higashida; L N Hopkins; M B Horowitz; S C Johnston; M W Lawton; M W McDermott; A M Malek; J P Mohr; A I Qureshi; H Riina; W S Smith; J Pile-Spellman; R F Spetzler; T A Tomsick; W L Young Journal: Stroke Date: 2001-06 Impact factor: 7.914
Authors: Andrew Molyneux; Richard Kerr; Irene Stratton; Peter Sandercock; Mike Clarke; Julia Shrimpton; Rury Holman Journal: Lancet Date: 2002-10-26 Impact factor: 79.321
Authors: C Stapf; H Mast; R R Sciacca; J H Choi; A V Khaw; E S Connolly; J Pile-Spellman; J P Mohr Journal: Neurology Date: 2006-05-09 Impact factor: 9.910
Authors: H J Barnett; D Sackett; D W Taylor; B Haynes; S J Peerless; I Meissner; V Hachinski; A Fox Journal: N Engl J Med Date: 1987-03-26 Impact factor: 91.245
Authors: Alexander X Halim; S Claiborne Johnston; Vineeta Singh; Charles E McCulloch; John P Bennett; Achal S Achrol; Stephen Sidney; William L Young Journal: Stroke Date: 2004-05-27 Impact factor: 7.914
Authors: A David Mendelow; Barbara A Gregson; Elise N Rowan; Gordon D Murray; Anil Gholkar; Patrick M Mitchell Journal: Lancet Date: 2013-05-29 Impact factor: 79.321
Authors: S Lang; P Gölitz; T Struffert; J Rösch; K Rössler; M Kowarschik; C Strother; A Doerfler Journal: AJNR Am J Neuroradiol Date: 2017-04-13 Impact factor: 3.825
Authors: K H Narsinh; K Mueller; J Nelson; J Massachi; D C Murph; A Z Copelan; S W Hetts; V V Halbach; R T Higashida; A A Abla; M R Amans; C F Dowd; H Kim; D L Cooke Journal: AJNR Am J Neuroradiol Date: 2020-10-29 Impact factor: 3.825